Allist Pharmaceuticals, Inc.

This study tests a daily pill called furmonertinib in about 100 people with advanced lung cancer that has a specific genetic change (EGFR exon 20 insertion) and has worsened after chemotherapy. The goal is to see if the drug can shrink tumors and control the disease. Participants…

This study tests an experimental drug called JAB-21822 (glecirasib) in people with advanced solid tumors that have a specific KRAS G12C mutation and have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it shrinks…

This study tests a combination of two drugs, JAB-21822 and cetuximab, in people with advanced colorectal, small intestine, or appendiceal cancers that have a specific KRAS G12C mutation. The goal is to see if the combination is safe and can shrink tumors. About 48 adults who have…

This early-stage study tests a new oral drug, furmonertinib mesilate, in 30 people with advanced non-small cell lung cancer that has a specific EGFR mutation (exon 20 insertion). The drug aims to shrink or control tumors. Participants include both those who have had prior treatme…